FY2025 EPS Estimate for Cullinan Therapeutics Cut by Analyst

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Investment analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Cullinan Therapeutics in a research note issued on Wednesday, January 29th. HC Wainwright analyst E. White now expects that the company will earn ($2.74) per share for the year, down from their previous forecast of ($2.55). HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2025 earnings at ($0.20) EPS and FY2026 earnings at ($3.15) EPS.

Cullinan Therapeutics (NASDAQ:CGEM) last issued its earnings results on Thursday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.09.

Separately, UBS Group assumed coverage on shares of Cullinan Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $30.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $32.50.

Cullinan Therapeutics Trading Up 1.4 %

Shares of CGEM opened at $10.20 on Monday. Cullinan Therapeutics has a 1-year low of $9.50 and a 1-year high of $30.19. The stock has a market capitalization of $593.95 million, a P/E ratio of -3.59 and a beta of -0.16. The business’s 50-day moving average price is $11.60 and its 200 day moving average price is $15.03.

Insider Activity at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 3,489 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $12.52, for a total transaction of $43,682.28. Following the transaction, the insider now owns 104,453 shares in the company, valued at approximately $1,307,751.56. This trade represents a 3.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Nadim Ahmed sold 8,400 shares of the company’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total transaction of $99,708.00. Following the completion of the sale, the chief executive officer now owns 263,150 shares of the company’s stock, valued at $3,123,590.50. This represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,582 shares of company stock valued at $246,977. Corporate insiders own 6.07% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Amalgamated Bank lifted its position in Cullinan Therapeutics by 97.3% during the 3rd quarter. Amalgamated Bank now owns 1,768 shares of the company’s stock worth $30,000 after acquiring an additional 872 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Cullinan Therapeutics in the fourth quarter valued at $136,000. China Universal Asset Management Co. Ltd. lifted its position in Cullinan Therapeutics by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,346 shares of the company’s stock worth $150,000 after purchasing an additional 1,195 shares during the period. New York State Common Retirement Fund boosted its stake in Cullinan Therapeutics by 32.9% during the fourth quarter. New York State Common Retirement Fund now owns 12,918 shares of the company’s stock worth $157,000 after buying an additional 3,200 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Cullinan Therapeutics in the 2nd quarter valued at $186,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.